Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies
Authors:
- Fabio PerrottaFPFabio Perrotta
- Domenica Francesca MarinielloDMDomenica Francesca Mariniello
- Giulia M. StellaGSGiulia M. Stella
- Raffaella PagliaroRPRaffaella Pagliaro
- Filippo ScialòFSFilippo Scialò
- Vasiliki LiakouliVLVasiliki Liakouli
- Giulio ForteGFGiulio Forte
- Francesco CicciaFCFrancesco Ciccia
- Andrea BiancoAndrea Bianco
- Vito D’AgnanoVDVito D’Agnano
Open Access
- 12 March 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2166
Abstract
Systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) comprises a heterogeneous group of fibrosing lung disorders frequently complicated by progressive pulmonary fibrosis, a phenotype associated with accelerated lung function decline and increased mortality. Although antifibrotic therapies have improved clinical outcomes, significant unmet needs remain, particularly regarding treatment tolerability and integration with background immunosuppressive strategies. Preferential phosphodiesterase-4B (PDE4B) inhibition has emerged as a novel therapeutic approach targeting both inflammatory and fibrotic pathways through modulation of intracellular cyclic adenosine monophosphate signaling. This narrative review summarizes the biological rationale and emerging clinical evidence supporting nerandomilast, an oral preferential PDE4B inhibitor, in autoimmune-associated interstitial lung diseases. Preclinical data indicate that PDE4B inhibition may attenuate fibroblast activation, inflammatory signaling, and extracellular matrix deposition. Clinical trials conducted in progressive pulmonary fibrosis populations have demonstrated a reduction in lung function decline, with subgroup analyses suggesting potential benefit in autoimmune-related diseases, although evidence remains limited. The safety profile appears mainly characterized by gastrointestinal adverse events, with ongoing evaluation of neuropsychiatric safety and drug interactions in complex autoimmune populations. Overall, nerandomilast represents a promising investigational strategy bridging antifibrotic and immunomodulatory mechanisms, warranting further dedicated studies in SARD-ILD.Keywords
This publication has 29 references indexed in Scilit:
- Fibroblasts as regulators of lung immunity, repair and fibrosisNature Reviews Immunology, 2026
- Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 TrialACR Open Rheumatology, 2025
- Unmet needs and emerging pharmacotherapies for autoimmune connective tissue disease-associated interstitial lung diseasesAutoimmunity Reviews, 2025
- Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune DisordersDrugs, 2024
- Évaluation de la pirfénidone chez les patients présentant une fibrose pulmonaire associée aux anticorps anti-myéloperoxydase (MPO) ou à une vascularite associée aux anti-MPO : résultats de l’essai prospectif PIRFENIVASLa Revue de Médecine Interne, 2022
- Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet Respiratory Medicine, 2022
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialThe Lancet Respiratory Medicine, 2021
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019